Zobrazeno 1 - 10
of 51
pro vyhledávání: ''
Autor:
Jinying Shen, Yujie Zhao, Linhai Zhong, Tianhui Hu, Xiong Chen, Xiaolin Xu, Daxuan Wang, Yan-yan Zhan, Xiaoting Hong, Hanwei Cao, Yitong Zhou, Jianben Wu, Ying Lin, Wenqing Zhang, Jihuan Hou
Publikováno v:
Cancer Research. 81:5904-5918
Invasive mucinous lung adenocarcinoma (IMA) is a subtype of lung adenocarcinoma with a strong invasive ability. IMA frequently carries "undruggable" KRAS mutations, highlighting the need for new molecular targets and therapies. Nuclear receptor HNF4
Autor:
Douglas R. Spitz, Vishnu Menon, Kevin Cho, Michael C. Zahner, Yuting Wang, Naoshad Muhammad, Jin Zhang, Ramachandran Rashmi, Julie K. Schwarz, Xiaojing Huang, Buck E. Rogers, Gary J. Patti, Sisi Zhang, Yi Huang, Michael L. McCormick, Kay Jayachandran, Fiona Ruiz
Publikováno v:
Mol Cancer Ther
The purpose of this study was to determine if radiation (RT)-resistant cervical cancers are dependent upon glutamine metabolism driven by activation of the PI3K pathway and test whether PI3K pathway mutation predicts radiosensitization by inhibition
Autor:
Sachin K. Khiste, Mohammad Burhan Uddin, Ronald A. Hill, Sami Nazzal, Zhijun Liu, Xin Gu, Salman B. Hosain, Kartik R. Roy, Yong-Yu Liu
Publikováno v:
Mol Cancer Ther
Ceramide (Cer) is an active cellular sphingolipid that can induce apoptosis or proliferation-arrest of cancer cells. Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to t
Autor:
Ruihua Bai, Tianshun Zhang, Yongping Song, Qingxin Xia, Kangdong Liu, Zigang Dong, Qiushi Wang, Xiang Li, Keke Wang, Xiaoyu Chang, Ting Wang, Ann M. Bode, Joohyun Ryu, Wei-Ya Ma
Publikováno v:
Cancer Prevention Research. 12:837-848
Lung cancer is the leading cause of cancer-related death worldwide. However, promising agents for lung cancer prevention are still very limited. Identification of preventive targets and novel effective preventive agents is urgently needed for clinica
Autor:
Takashi Kojima, Masahiro Yasunaga, Kenji Hirotani, Yasutoshi Kuboki, Toshihiko Doi, Takashi Kagari, Yoshikatsu Koga, Naoyuki Maeda, Yasuhiro Matsumura, Mayumi Yamauchi, Shigehiro Koganemaru
Publikováno v:
Molecular Cancer Therapeutics. 18:2043-2050
HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody–drug conjugate (ADC)
Publikováno v:
Clinical Cancer Research. 25:4141-4154
Purpose: Hepatocellular carcinoma (HCC), one of the most common and deadliest malignancies worldwide, has a poor prognosis, owing to its high potential for vascular invasion and metastasis and the lack of biomarkers for early diagnosis. Thus, it must
Autor:
Alena Cristina Jaime-Ramirez, Yeshavanth Kumar Banasavadi-Siddegowda, Haroon Quadri, Tejaswini Nallanagulagari, Balveen Kaur, Mitra Nair, Tae Jin Lee, Manish K. Aghi, Ji Young Yoo, W. Shawn Carbonell, Joseph N. Liu, Kurt H. Bockhorst, Jeffrey Yunhua Guo, Jianying Zhang
Publikováno v:
Mol Cancer Ther
Integrin β1 receptor, expressed on the surface of tumor cells and macrophages in the tumor microenvironment (TME), has been implicated in both tumor progression and resistance to multiple modalities of therapy. OS2966 is the first clinical-ready hum
Autor:
Michael B. Sporn, Di Zhang, Samir J. Ibrahim, Karen T. Liby, Ana S. Leal, Pamela A. Marshall, Carl E. Wagner, Pritika H. Shahani, San Raban, Peter W. Jurutka, Sarah Carapellucci, Jaskaran S. Bhogal
Publikováno v:
Cancer Prevention Research. 12:211-224
Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing many types of cancer. However, the limited efficacy and undesirable lipidemic side-effects of the only clinically approved rexinoid, bexarotene, drive the s
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Isaac K. Nardi, Dan J. Raz, Lu Yang, Jinhui Wang, Jami Wang, Rajendra P. Pangeni, Xinwei Yun, Melissa Bonner, Ming Gao, Keqiang Zhang, Jun Wu
Publikováno v:
Molecular Cancer Research. 16:1161-1171
Loss of monoubiquitination of histone H2B (H2Bub1) was found to be associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. This study investigated the association and impact of the ubiquitin-specific peptidase 22 (USP22),